18F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer
Open Access
- 18 January 2023
- journal article
- research article
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 39, 100583
Abstract
No abstract availableKeywords
Funding Information
- Hamilton Health Sciences Foundation
This publication has 30 references indexed in Scilit:
- Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate CancerMolecular Imaging and Biology, 2015
- Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate CancerMolecular Imaging and Biology, 2015
- Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigenProceedings of the National Academy of Sciences, 2011
- Androgen‐responsive and ‐unresponsive prostate cancer cell lines respond differently to stimuli inducing neuroendocrine differentiationInternational Journal of Andrology, 2010
- Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant MetastasisPathology and Oncology Research, 2008
- Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3Archives of Biochemistry and Biophysics, 2005
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- P504SAmerican Journal of Surgical Pathology, 2001
- N‐AcetylaspartylglutamateJournal of Neurochemistry, 2000
- Upregulation of prostate-specific membrane antigen after androgen-deprivation therapyUrology, 1996